vs

Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and OneMedNet Corp (ONMD). Click either name above to swap in a different company.

MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $890.0K, roughly 5.4× OneMedNet Corp). MAXCYTE, INC. runs the higher net margin — -200.5% vs -352.8%, a 152.3% gap on every dollar of revenue. On growth, OneMedNet Corp posted the faster year-over-year revenue change (3323.1% vs -20.9%). OneMedNet Corp produced more free cash flow last quarter ($-1.7M vs $-2.9M). Over the past eight quarters, OneMedNet Corp's revenue compounded faster (89.4% CAGR vs -7.4%).

MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.

OneMedNet Corp is a U.S.-headquartered healthcare tech firm offering secure cloud-based data sharing and workflow solutions for medical imaging and patient health information. It serves healthcare providers, insurance payers, and life sciences groups, with its core operating market centered in North America.

MXCT vs ONMD — Head-to-Head

Bigger by revenue
MXCT
MXCT
5.4× larger
MXCT
$4.8M
$890.0K
ONMD
Growing faster (revenue YoY)
ONMD
ONMD
+3344.0% gap
ONMD
3323.1%
-20.9%
MXCT
Higher net margin
MXCT
MXCT
152.3% more per $
MXCT
-200.5%
-352.8%
ONMD
More free cash flow
ONMD
ONMD
$1.2M more FCF
ONMD
$-1.7M
$-2.9M
MXCT
Faster 2-yr revenue CAGR
ONMD
ONMD
Annualised
ONMD
89.4%
-7.4%
MXCT

Income Statement — Q4 2025 vs Q4 2025

Metric
MXCT
MXCT
ONMD
ONMD
Revenue
$4.8M
$890.0K
Net Profit
$-9.6M
$-3.1M
Gross Margin
20.7%
Operating Margin
-234.5%
-353.4%
Net Margin
-200.5%
-352.8%
Revenue YoY
-20.9%
3323.1%
Net Profit YoY
9.4%
-32.3%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MXCT
MXCT
ONMD
ONMD
Q4 25
$4.8M
$890.0K
Q3 25
$4.6M
$177.0K
Q2 25
$5.8M
$155.0K
Q1 25
$5.7M
$137.0K
Q4 24
$6.1M
$26.0K
Q3 24
$5.6M
$142.0K
Q2 24
$5.0M
$227.0K
Q1 24
$5.6M
$248.0K
Net Profit
MXCT
MXCT
ONMD
ONMD
Q4 25
$-9.6M
$-3.1M
Q3 25
$-12.4M
$-741.0K
Q2 25
$-12.4M
$3.0M
Q1 25
$-10.3M
$-1.9M
Q4 24
$-10.6M
$-2.4M
Q3 24
$-11.6M
$-2.1M
Q2 24
$-9.4M
$-3.6M
Q1 24
$-9.5M
$-2.1M
Gross Margin
MXCT
MXCT
ONMD
ONMD
Q4 25
20.7%
Q3 25
-125.4%
Q2 25
-155.5%
Q1 25
-163.5%
Q4 24
-100.0%
Q3 24
-59.2%
Q2 24
-44.9%
Q1 24
-27.8%
Operating Margin
MXCT
MXCT
ONMD
ONMD
Q4 25
-234.5%
-353.4%
Q3 25
-307.4%
-1262.7%
Q2 25
-244.3%
-1331.0%
Q1 25
-214.1%
-1623.4%
Q4 24
-213.1%
-10438.5%
Q3 24
-250.4%
-1645.1%
Q2 24
-241.0%
-1081.1%
Q1 24
-219.8%
-847.2%
Net Margin
MXCT
MXCT
ONMD
ONMD
Q4 25
-200.5%
-352.8%
Q3 25
-269.7%
-418.6%
Q2 25
-212.2%
1923.9%
Q1 25
-178.7%
-1388.3%
Q4 24
-175.0%
-9126.9%
Q3 24
-205.9%
-1449.3%
Q2 24
-188.8%
-1581.1%
Q1 24
-170.6%
-850.4%
EPS (diluted)
MXCT
MXCT
ONMD
ONMD
Q4 25
$-0.06
Q3 25
$-0.12
$-0.01
Q2 25
$-0.12
$0.07
Q1 25
$-0.06
Q4 24
$-0.07
Q3 24
$-0.11
$-0.07
Q2 24
$-0.09
$-0.14
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MXCT
MXCT
ONMD
ONMD
Cash + ST InvestmentsLiquidity on hand
$103.0M
$585.0K
Total DebtLower is stronger
$220.0K
Stockholders' EquityBook value
$171.5M
$-3.0M
Total Assets
$202.5M
$2.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MXCT
MXCT
ONMD
ONMD
Q4 25
$103.0M
$585.0K
Q3 25
$105.7M
$149.0K
Q2 25
$126.6M
$122.0K
Q1 25
$138.3M
$144.0K
Q4 24
$154.5M
$172.0K
Q3 24
$153.8M
$1.9M
Q2 24
$157.3M
$407.0K
Q1 24
$157.5M
$174.0K
Total Debt
MXCT
MXCT
ONMD
ONMD
Q4 25
$220.0K
Q3 25
Q2 25
Q1 25
$2.3M
Q4 24
$2.3M
Q3 24
$2.3M
Q2 24
$2.4M
Q1 24
Stockholders' Equity
MXCT
MXCT
ONMD
ONMD
Q4 25
$171.5M
$-3.0M
Q3 25
$180.3M
$-3.9M
Q2 25
$190.7M
$-3.8M
Q1 25
$199.4M
$-16.6M
Q4 24
$206.3M
$-15.9M
Q3 24
$213.3M
$-14.3M
Q2 24
$221.3M
$-19.2M
Q1 24
$226.4M
$-15.7M
Total Assets
MXCT
MXCT
ONMD
ONMD
Q4 25
$202.5M
$2.2M
Q3 25
$213.5M
$1.5M
Q2 25
$219.8M
$2.3M
Q1 25
$230.0M
$1.7M
Q4 24
$239.5M
$3.7M
Q3 24
$248.6M
$4.4M
Q2 24
$251.5M
$1.0M
Q1 24
$257.9M
$750.0K

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MXCT
MXCT
ONMD
ONMD
Operating Cash FlowLast quarter
$-2.7M
$-1.7M
Free Cash FlowOCF − Capex
$-2.9M
$-1.7M
FCF MarginFCF / Revenue
-61.0%
-193.0%
Capex IntensityCapex / Revenue
4.8%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-36.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MXCT
MXCT
ONMD
ONMD
Q4 25
$-2.7M
$-1.7M
Q3 25
$-7.5M
$-1.6M
Q2 25
$-9.9M
$-2.3M
Q1 25
$-14.4M
$-1.9M
Q4 24
$-7.8M
$-2.0M
Q3 24
$-4.4M
$-1.9M
Q2 24
$-4.8M
$-1.5M
Q1 24
$-10.6M
$-1.5M
Free Cash Flow
MXCT
MXCT
ONMD
ONMD
Q4 25
$-2.9M
$-1.7M
Q3 25
$-7.8M
Q2 25
$-10.4M
$-2.3M
Q1 25
$-15.1M
$-2.0M
Q4 24
$-8.0M
$-2.0M
Q3 24
$-4.8M
$-1.9M
Q2 24
$-5.1M
$-1.5M
Q1 24
$-11.4M
$-1.6M
FCF Margin
MXCT
MXCT
ONMD
ONMD
Q4 25
-61.0%
-193.0%
Q3 25
-168.5%
Q2 25
-179.2%
-1475.5%
Q1 25
-262.3%
-1425.5%
Q4 24
-131.6%
-7811.5%
Q3 24
-85.5%
-1346.5%
Q2 24
-103.3%
-663.9%
Q1 24
-203.6%
-626.2%
Capex Intensity
MXCT
MXCT
ONMD
ONMD
Q4 25
4.8%
0.6%
Q3 25
6.5%
0.0%
Q2 25
10.0%
1.9%
Q1 25
11.4%
3.6%
Q4 24
2.4%
134.6%
Q3 24
7.2%
6.3%
Q2 24
5.9%
0.4%
Q1 24
14.4%
2.4%
Cash Conversion
MXCT
MXCT
ONMD
ONMD
Q4 25
Q3 25
Q2 25
-0.77×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons